TWI854285B - 抗體介導屈公(chikungunya)病毒中和 - Google Patents

抗體介導屈公(chikungunya)病毒中和 Download PDF

Info

Publication number
TWI854285B
TWI854285B TW111131757A TW111131757A TWI854285B TW I854285 B TWI854285 B TW I854285B TW 111131757 A TW111131757 A TW 111131757A TW 111131757 A TW111131757 A TW 111131757A TW I854285 B TWI854285 B TW I854285B
Authority
TW
Taiwan
Prior art keywords
cdata
antibody
antigen
binding fragment
ser
Prior art date
Application number
TW111131757A
Other languages
English (en)
Chinese (zh)
Other versions
TW202248210A (zh
Inventor
詹姆士 E 二世 克勞
史考特 A 史密斯
特倫斯 德瑪帝
萊芮 席爾瓦
Original Assignee
美國凡德貝爾大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國凡德貝爾大學 filed Critical 美國凡德貝爾大學
Publication of TW202248210A publication Critical patent/TW202248210A/zh
Application granted granted Critical
Publication of TWI854285B publication Critical patent/TWI854285B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/18Togaviridae; Flaviviridae
    • G01N2333/181Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/10Detection of antigens from microorganism in sample from host
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
TW111131757A 2015-04-14 2016-04-14 抗體介導屈公(chikungunya)病毒中和 TWI854285B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562147354P 2015-04-14 2015-04-14
US62/147,354 2015-04-14

Publications (2)

Publication Number Publication Date
TW202248210A TW202248210A (zh) 2022-12-16
TWI854285B true TWI854285B (zh) 2024-09-01

Family

ID=57126199

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111131757A TWI854285B (zh) 2015-04-14 2016-04-14 抗體介導屈公(chikungunya)病毒中和
TW105111764A TWI772257B (zh) 2015-04-14 2016-04-14 抗體介導屈公(chikungunya)病毒中和

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW105111764A TWI772257B (zh) 2015-04-14 2016-04-14 抗體介導屈公(chikungunya)病毒中和

Country Status (27)

Country Link
US (2) US10787503B2 (enExample)
EP (1) EP3283101A4 (enExample)
JP (3) JP6979875B2 (enExample)
KR (2) KR102736152B1 (enExample)
CN (2) CN107708726B (enExample)
AR (1) AR104264A1 (enExample)
AU (2) AU2016250188C1 (enExample)
CA (2) CA2982491C (enExample)
CL (1) CL2017002596A1 (enExample)
CO (1) CO2017010316A2 (enExample)
CR (2) CR20170518A (enExample)
DO (1) DOP2017000236A (enExample)
EA (1) EA037060B1 (enExample)
EC (1) ECSP17075750A (enExample)
HK (1) HK1246671A1 (enExample)
IL (2) IL290449B2 (enExample)
MA (1) MA41517A (enExample)
MX (2) MX2017013286A (enExample)
MY (1) MY191666A (enExample)
NZ (1) NZ736445A (enExample)
PE (2) PE20180171A1 (enExample)
PH (2) PH12021500048A1 (enExample)
SG (2) SG11201708152SA (enExample)
TN (1) TN2017000438A1 (enExample)
TW (2) TWI854285B (enExample)
UA (1) UA125206C2 (enExample)
WO (1) WO2016168417A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗chikv抗體及其用途
KR102029394B1 (ko) * 2017-11-14 2019-10-07 재단법인 바이오나노헬스가드연구단 치쿤구니아 바이러스 감염 진단용 단일클론항체, 이를 생산하는 하이브리도마 및 이를 이용한 치쿤구니아 바이러스 감염 진단 방법
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
WO2019156758A2 (en) * 2018-01-05 2019-08-15 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
JP6906207B2 (ja) * 2018-02-09 2021-07-21 国立大学法人大阪大学 チクングニアウイルス検出用免疫クロマト分析装置
JP7359390B2 (ja) * 2018-02-09 2023-10-11 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
WO2019236875A1 (en) * 2018-06-06 2019-12-12 Albert Einstein College Of Medicine, Inc. Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same
US20230065377A1 (en) * 2019-08-31 2023-03-02 Vanderbilt University Human antibodies to alphaviruses
KR102202082B1 (ko) * 2019-09-25 2021-01-11 충북대학교 산학협력단 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN110922478B (zh) * 2019-12-07 2021-07-30 中国人民解放军军事科学院军事医学研究院 针对特异表位的抗基孔肯雅热的全人源单克隆抗体及应用
WO2022101805A1 (en) * 2020-11-13 2022-05-19 Emergent Biosolutions Canada Inc. Hyperimmune globulins for treatment of chikungunya virus infections
CN118956771A (zh) * 2024-04-24 2024-11-15 华南农业大学 一种杂交瘤细胞株、基孔肯雅病毒单克隆抗体及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015010125A1 (en) * 2013-07-19 2015-01-22 Integral Molecular, Inc. Antibodies against chikungunya virus and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516395B (zh) * 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
CA2598966A1 (en) 2007-09-07 2009-03-07 Institut Pasteur Anti-chikungunya monoclonal antibodies and uses thereof
US9000131B2 (en) * 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
TW202300515A (zh) * 2016-10-20 2023-01-01 法商賽諾菲公司 抗chikv抗體及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015010125A1 (en) * 2013-07-19 2015-01-22 Integral Molecular, Inc. Antibodies against chikungunya virus and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Selvarajah, Suganya, et al. "A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease." PLoS Negl Trop Dis 7.9 (2013): e2423, p.1-11. *

Also Published As

Publication number Publication date
KR102736152B1 (ko) 2024-11-28
JP6979875B2 (ja) 2021-12-15
DOP2017000236A (es) 2017-12-15
KR20230087616A (ko) 2023-06-16
US11345743B2 (en) 2022-05-31
US10787503B2 (en) 2020-09-29
CA2982491A1 (en) 2016-10-20
MY191666A (en) 2022-07-06
EP3283101A4 (en) 2019-01-16
AU2022202819C1 (en) 2025-04-03
CA3176525A1 (en) 2016-10-20
PE20180171A1 (es) 2018-01-22
JP2021144047A (ja) 2021-09-24
WO2016168417A3 (en) 2017-01-05
AU2016250188C1 (en) 2022-08-11
IL290449B1 (en) 2023-12-01
TWI772257B (zh) 2022-08-01
ECSP17075750A (es) 2018-02-28
CN114478756A (zh) 2022-05-13
AU2016250188B2 (en) 2022-02-03
PE20220297A1 (es) 2022-03-07
SG10202107295XA (en) 2021-08-30
US20180079802A1 (en) 2018-03-22
CR20170518A (es) 2018-01-25
CA2982491C (en) 2023-08-29
BR112017021952A2 (pt) 2018-07-10
UA125206C2 (uk) 2022-02-02
EA201792220A1 (ru) 2018-03-30
CN107708726B (zh) 2022-01-14
IL290449B2 (en) 2024-04-01
NZ736445A (en) 2023-06-30
CL2017002596A1 (es) 2018-05-18
TN2017000438A1 (en) 2019-04-12
TW201643189A (zh) 2016-12-16
IL254891B (en) 2022-03-01
WO2016168417A2 (en) 2016-10-20
TW202248210A (zh) 2022-12-16
MX2017013286A (es) 2018-06-19
PH12017501865A1 (en) 2018-03-05
KR102541905B1 (ko) 2023-06-12
US20200277359A1 (en) 2020-09-03
AU2016250188A1 (en) 2017-11-02
NZ775007A (en) 2024-08-30
AU2022202819A1 (en) 2022-05-19
AR104264A1 (es) 2017-07-05
CN114478756B (zh) 2024-08-23
KR20180004403A (ko) 2018-01-11
JP2022174144A (ja) 2022-11-22
JP2018520334A (ja) 2018-07-26
MX2021013207A (es) 2021-12-10
MA41517A (fr) 2017-12-19
HK1246671A1 (zh) 2018-09-14
SG11201708152SA (en) 2017-11-29
AU2022202819B2 (en) 2024-09-12
IL290449A (en) 2022-04-01
EA037060B1 (ru) 2021-02-01
CR20210438A (es) 2021-10-04
CO2017010316A2 (es) 2017-12-15
CN107708726A (zh) 2018-02-16
IL254891A0 (en) 2017-12-31
JP7536059B2 (ja) 2024-08-19
EP3283101A2 (en) 2018-02-21
PH12021500048A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
AU2022202819C1 (en) Antibody-mediated neutralization of Chikungunya virus
KR20220038415A (ko) 엔테로바이러스 d68에 대한 인간 모노클로날 항체
CN115768790A (zh) 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体
KR20110047193A (ko) 중화 항-인플루엔자 a 바이러스 항체 및 이의 용도
KR102880907B1 (ko) 한타바이러스에 대한 인간 모노클로날 항체 및 이의 사용 방법
US11851478B2 (en) Antibody-mediated neutralization of chikungunya virus
HK40072444A (en) Antibody-mediated neutralization of chikungunya virus
HK40072444B (zh) 抗体介导的切昆贡亚热病毒的中和
KR20220103761A (ko) 지카 바이러스를 중화하는 인간 항체 및 이의 사용 방법
AU2020273365A1 (en) Human antibodies to Ross River virus and methods of use therefor
EA049454B1 (ru) ЧЕЛОВЕЧЕСКИЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА К КОРОНАВИРУСУ ТЯЖЕЛОГО ОСТРОГО РЕСПИРАТОРНОГО СИНДРОМА 2 (SARS-CoV-2)
BR112017021952B1 (pt) Anticorpo monoclonal recombinante, seus usos, composição farmacêutica, métodos para produção do dito anticorpo bem como para detecção de uma infecção com vírus chikungunya em um indivíduo, e kit